艾伯维公司宣布,其药物Epcoritamab联合来那度胺,在治疗复发或难治性弥漫性大B细胞淋巴瘤患者的三期临床试验中,取得了积极成果。这一关键性研究的正面数据,为这种侵袭性淋巴瘤患者带来了新的治疗希望。
艾伯维公司宣布,其药物Epcoritamab联合来那度胺,在治疗复发或难治性弥漫性大B细胞淋巴瘤患者的三期临床试验中,取得了积极成果。这一关键性研究的正面数据,为这种侵袭性淋巴瘤患者带来了新的治疗希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.